Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)

NCT07730632 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

IgAN - IgA Nephropathy
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
C3 Glomerulopathy (C3G)
Primary Membranous Nephropathy

Interventions

DRUG: QLS7305 Injection

Sponsor

Qilu Pharmaceutical Co., Ltd.